Hypoxia and drug resistance - PubMed (original) (raw)

Review

Hypoxia and drug resistance

B A Teicher. Cancer Metastasis Rev. 1994 Jun.

Abstract

Biologically and therapeutically important hypoxia occurs in many solid tumor masses. Hypoxia can be a direct cause of therapeutic resistance because some drugs and radiation require oxygen to be maximally cytotoxic. Cellular metabolism is altered under hypoxic conditions. Hypoxia can result in drug resistance indirectly if under this condition cells more effectively detoxify the drug molecules. Finally, there is evidence that hypoxia can enhance genetic instability in tumor cells thus allowing more rapid development of drug resistance cells. The current review describes the effects of hypoxia on tumor response to a variety of anti-cancer agents and also describes progress toward therapeutically useful methods of delivering oxygen to tumors in an effort to overcome therapeutic resistance due to hypoxia. Finally, the use of hypoxic cell selective cytotoxic agents as a means of addressing hypoxic 'drug resistance' is discussed.

PubMed Disclaimer

Similar articles

• In vitro testing of chemosensitivity in physiological hypoxia.
  Grigoryan R, Keshelava N, Anderson C, Reynolds CP. Grigoryan R, et al. Methods Mol Med. 2005;110:87-100. doi: 10.1385/1-59259-869-2:087. Methods Mol Med. 2005. PMID: 15901930
• The Antiproliferative and Colony-suppressive Activities of STAT3 Inhibitors in Human Cancer Cells Is Compromised Under Hypoxic Conditions.
  Tian J, Xiao H, Wu R, Cao Y, Li C, Xu R, Pierson CR, Finlay JL, Yang F, Gu N, Lin J. Tian J, et al. Anticancer Res. 2017 Feb;37(2):547-553. doi: 10.21873/anticanres.11347. Anticancer Res. 2017. PMID: 28179300 Free PMC article.
• Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
  Phillips RM. Phillips RM. Cancer Chemother Pharmacol. 2016 Mar;77(3):441-57. doi: 10.1007/s00280-015-2920-7. Epub 2016 Jan 25. Cancer Chemother Pharmacol. 2016. PMID: 26811177 Free PMC article. Review.
• SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
  Brown JM. Brown JM. Br J Cancer. 1993 Jun;67(6):1163-70. doi: 10.1038/bjc.1993.220. Br J Cancer. 1993. PMID: 8512801 Free PMC article. Review.
• Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.
  Ebbesen P, Pettersen EO, Gorr TA, Jobst G, Williams K, Kieninger J, Wenger RH, Pastorekova S, Dubois L, Lambin P, Wouters BG, Van Den Beucken T, Supuran CT, Poellinger L, Ratcliffe P, Kanopka A, Görlach A, Gasmann M, Harris AL, Maxwell P, Scozzafava A. Ebbesen P, et al. J Enzyme Inhib Med Chem. 2009 Apr;24 Suppl 1:1-39. doi: 10.1080/14756360902784425. J Enzyme Inhib Med Chem. 2009. PMID: 19330638 Review.

Cited by

• Synthesis and evaluation of sulfonamide derivatives of quinoxaline 1,4-dioxides as carbonic anhydrase inhibitors.
  Buravchenko GI, Scherbakov AM, Krymov SK, Salnikova DI, Zatonsky GV, Schols D, Vullo D, Supuran CT, Shchekotikhin AE. Buravchenko GI, et al. RSC Adv. 2024 Jul 23;14(32):23257-23272. doi: 10.1039/d4ra04548c. eCollection 2024 Jul 19. RSC Adv. 2024. PMID: 39045402 Free PMC article.
• Identification and Development of Cyclic Peptide Inhibitors of Hypoxia Inducible Factors 1 and 2 That Disrupt Hypoxia-Response Signaling in Cancer Cells.
  Ball AT, Mohammed S, Doigneaux C, Gardner RM, Easton JW, Turner S, Essex JW, Pairaudeau G, Tavassoli A. Ball AT, et al. J Am Chem Soc. 2024 Apr 3;146(13):8877-8886. doi: 10.1021/jacs.3c10508. Epub 2024 Mar 19. J Am Chem Soc. 2024. PMID: 38503564 Free PMC article.
• Fe-doped nanodiamond-based photo-Fenton catalyst for dual-modal fluorescence imaging and improved chemotherapeutic efficacy against tumor hypoxia.
  Selvam R, Pearl WG, Perevedentseva E, Karmenyan A, Cheng CL. Selvam R, et al. RSC Adv. 2024 Jan 31;14(6):4285-4300. doi: 10.1039/d3ra08465e. eCollection 2024 Jan 23. RSC Adv. 2024. PMID: 38298935 Free PMC article.
• The action and resistance mechanisms of Lenvatinib in liver cancer.
  Buttell A, Qiu W. Buttell A, et al. Mol Carcinog. 2023 Dec;62(12):1918-1934. doi: 10.1002/mc.23625. Epub 2023 Sep 6. Mol Carcinog. 2023. PMID: 37671815 Review.
• Cytotoxicity of Ruthenium(II) Arene Complexes Containing Functionalized Ferrocenyl β-Diketonate Ligands.
  Allison M, Caramés-Méndez P, Hofmann BJ, Pask CM, Phillips RM, Lord RM, McGowan PC. Allison M, et al. Organometallics. 2023 Jul 5;42(15):1869-1881. doi: 10.1021/acs.organomet.2c00553. eCollection 2023 Aug 14. Organometallics. 2023. PMID: 37592952 Free PMC article.

References

1. 1. Biochem Pharmacol. 1985 Dec 15;34(24):4191-5 - PubMed
2. 1. J Natl Cancer Inst. 1967 Oct;39(4):639-52 - PubMed
3. 1. Biochem Biophys Res Commun. 1979 Mar 30;87(2):649-53 - PubMed
4. 1. Cancer Res. 1985 Jan;45(1):213-6 - PubMed
5. 1. Cancer Res. 1982 Dec;42(12):4921-6 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations